Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Narra J

Unveiling the impacts of metformin on hepatocellular carcinoma: A bioinformatic exploration in cell lines Soraya, Soraya; Arfianti, Arfianti; Adikusuma, Wirawan; Irham, Lalu M.; Hamidy, Muhammad Y.; Winarto, Winarto; Rangkuti, Ina F.; Darmawi, Darmawi
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.968

Abstract

The most common type of liver cancer is hepatocellular carcinoma (HCC), accounting for 75–85% of cases. Despite its associated side effects, sorafenib remains the standard treatment for HCC. Given the critical need to improve therapeutic efficacy while minimizing adverse effects, alternative drugs must be thoroughly investigated. Numerous studies indicate that combining sorafenib with metformin results in a more favorable treatment profile. The aim of this study was to employ bioinformatics methodologies to elucidate the molecular pathways and genetic underpinnings of metformin's efficacy in HCC treatment. Genes associated with metformin and its action against HCC (Huh-7 and HepG2 cells) were acquired from the NCBI-GEO data collection by utilizing pre-determined keywords. Subsequently, pathways implicated in metformin-mediated HCC treatment were analyzed through the Kyoto Encyclopedia of Genes and Genomes (KEGG). Our analysis revealed the involvement of multiple pathways, with metabolic pathways implicated in 80% of the total cases. Neurodegenerative pathways were involved in only around 60% of the total cases. These findings align with the multifaceted mechanisms of metformin’s action, encompassing adenosine monophosphate-activated protein kinase activation, apoptosis induction, insulin regulation, anti-inflammatory responses, and modulation of cell proliferation. This comprehensive investigation sheds light on the intricate molecular landscape underpinning metformin's therapeutic efficacy in HCC, thereby informing potential avenues for optimizing treatment strategies.
Co-Authors A. Octamaya Tenri Awaru Adhe S, Maulidya Agus Widodo Agustin, Noor Isti Agustina, Utari Ahmad Mustofa Aisyah, Noor Akbar Putra, Fajir Al Farizi, Zulham Ali Imran Arfianti Arfianti Arianto Arianto Ariwati, Valentina Dili Asih, Hastin Atas Augusaskiani, Mutiara Alif Auliani, Firda Ayu, Welinda Dyah Azizah, Safira B2092151009, PERDHIANSYAH Cahyowati, Anik Cantika, Rahardina Dwi Darmawi Darmawi Darwis, M Eka Kumalasari Ekawaty, Dian Enos Lolang Fitri Wahyuni Hamidy, Muhammad Y. Hayatun Nufus Heriyadi, M. Hidayat, Nurohmat Ika Kurnia Indriani Ika Niswatin Budiarti Illahi, Fitrah Shafran Imsar Gunawan Indrayadi Indrayadi Indriani, Ika Kurnia Irham, Lalu M. Khairunnisa Khairunnisa Kurnia, Ika Kurniasih, Ninik Kusuma Agdhi Rahwana Linda Suherma Mahyus, Mahyus Manik Sunuantari Marhaeni Widiastuti, Tri Masithah, St. Mawan, M. Syafiudin Aris Mualimin Mualimin Muratno, Muratno Murti Puspita Rukmi Najah, Lulu Ah Natasari, Peni Sriwahyu Natasya, Cindy Nawangwulan, Kurniati Nindy Oktoriani, Ervita Nur Azizah Nur Istiqamah, Nur Nur, Uray M. Nurfatun, Nurfatun Nurul Sasmita, Nurul Nurus Soimah Nyipto Wibowo, Gentur Wahyu Oktoriani, Ervita Nindy Palupi, Nurul Azizah Putri Prasetyo, Henri Putri Lestari, Putri Rabiatul Adawiyah Rachmawati Rachmawati Rakhmat, Cece Ramadhan, Algi Rifalgi Rangkuti, Ina F. Ratna Sari Renata S, Adisty Radika Rianto, Leonov Rinawati, Siti Mardiastuti Riski, Akhmad Risti Rahmaniar Riza Alfian Safira Hasna Santi, Kussusanti Saswati, Risna Sawitri, Sari Sepang, Nurul Robbi Siti Uswatun Hasanah Siwi, Theresia Sri Widiastuti, Sri Suandi, Ipan Syafruddin Syafruddin Tashadi Tarmizi Wahyudi Wahyudi Wahyuni, Amaliyah Winarto Winarto Wirawan Adikusuma Yanti, Inda Hadi Yohanes Adi Nugroho Yuliana, Elsa Sari Yumassik, Abdul Mahmud Yusfik, Yusnita